This trial is testing a combination of two drugs, Ribociclib and Everolimus, to treat patients with advanced dedifferentiated liposarcoma or leiomyosarcoma who have had at least one prior systemic therapy. The drugs will be given orally, and the trial will last until disease progression, unacceptable toxicity, or withdrawal of consent.
1 Primary · 4 Secondary · Reporting Duration: Through study completion
50 Total Participants · 2 Treatment Groups
Primary Treatment: Ribociclib · No Placebo Group · Phase 2
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: